Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert synthesis of clinical trial data and guidelines without systematic review methodology.
PubMed 34757064 · doi:10.1016/j.jaip.2021.10.037
What was done
This narrative review summarizes clinical data and guidelines regarding hypogammaglobulinemia in patients treated with five FDA-approved CAR T-cell therapies and other investigational products (including BCMA-, SLAM-, and kappa light chain-directed therapies). It covers onset, duration, immune recovery, infection risks, differences between pediatric and adult populations, and management strategies for immunoglobulin replacement.
What was found
The abstract reports no quantitative data or numerical outcomes. It describes B-cell aplasia as an expected on-target, off-tumor effect that leads to hypogammaglobulinemia, notes variation between pediatric and adult populations, and outlines current organizational guidelines and expert recommendations for evaluation and immunoglobulin replacement therapy.
Why it matters
As CAR T-cell therapies expand into broader clinical use, secondary hypogammaglobulinemia and B-cell aplasia present substantial long-term infection risks. Consolidating monitoring and replacement strategies aids clinical management in this immunocompromised population.
Limits
As a narrative review, it lacks systematic search methodology, risk-of-bias assessment, and quantitative synthesis. Specific infection rates, hypogammaglobulinemia incidence metrics, and patient sample sizes are not provided in the abstract.
Cited by
- supports The human body can tolerate the collateral destruction of healthy B cells caused by CD19-targeted CAR T-cell therapy.